bluebird bio, Inc. (BLUE): $29.21

-0.69 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

bluebird bio Inc (BLUE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering bluebird bio Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
21 $146 $50 $82.33 $30.23 172.35%

The Trend in the Analyst Price Target


BLUE's average price target has moved down $26.73 over the prior 167 days.

Over the past 167 days, BLUE's average upside potential has been 78.52%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2020-11-23 21 146 50 82.33 42.73 92.67%
2020-11-11 20 146 50 80.05 45.48 76.01%
2020-10-21 19 196 68 106.26 54.34 95.55%
2020-09-26 18 196 68 105.33 57.04 84.66%
2020-08-26 18 196 68 105.33 56.41 86.72%
2020-08-07 18 196 68 105.33 63.48 65.93%
2020-07-25 18 215 70 109.06 64.24 69.77%
2020-07-13 18 215 70 109.06 60.71 79.64%
2020-06-12 18 215 70 109.28 63.93 70.94%
2020-06-09 18 215 70 109.06 66.77 63.34%

BLUE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.46 9 9 7 0 0 25

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • bluebird bio Inc's variance in analysts' estimates is less than 2.76000000000001% of all US stocks.
  • bluebird bio Inc's upside potential (average analyst target price relative to current price) is greater than 99.8% of stocks in the large market cap category.
  • BLUE has a greater number of analysts covering the stock than 97.95% of Pharmaceutical Products stocks.
  • bluebird bio Inc's average analyst price target is higher than 89.17% of Pharmaceutical Products stocks.

Stocks similar to bluebird bio Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are NBIX, GBT and SRPT.

Is BLUE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7245 seconds.